Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 38Lung Neoplasms 9Adenocarcinoma of Lung 9NSCLC 5Brain Neoplasms 5Adenocarcinoma, Bronchiolo-Alveolar 3Neoplasms 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Skin Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Non-Small-Cell Lung 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors 1EGFR Mutation Positive Non-small Cell Lung Cancer 1Drug-Related Side Effects and Adverse Reactions 1Breast Neoplasms 1Advanced Stage Non Small Cell Lung Cancer 1Advanced Non-small Cell Lung Cancer 1Advanced NSCLC With EGFR Mutation 1

Interventions

S 1 (combination) 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced NSCLC With EGFR Mutation × Gefitinib × Clear all
NCT03457337 2020-07-10

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Henan Cancer Hospital

Phase 2 Unknown
200 enrolled
Thoracic

Advanced NSCLC With EGFR Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡